News ArticleRBL Bank Hosts One-on-One Investor Meet with ASK Asset Management in Mumbai Without Disclosing Price Sensitive Information
Meeting held on November 3, 2026, adhering to SEBI Listing Regulations and information posted on RBL Bank website
RBL Bank conducted a one-on-one investor meeting with ASK Asset Management Private Limited in Mumbai on November 3, 2026. The bank confirmed that no unpublished price sensitive information was shared during this meeting, complying with SEBI Listing Regulations. Details have been made available on RBL Bank's official website.
RBL Bank Limited
General / Other
On November 3, 2026, RBL Bank Limited held a one-on-one physical investor meeting with ASK Asset Management Private Limited in Mumbai, ensuring compliance with SEBI Listing Regulations by not sharing any unpublished price sensitive information.
The meeting was conducted physically at Mumbai, aiming to engage with investors while adhering strictly to regulatory requirements.
RBL Bank confirmed that no unpublished price sensitive information (UPSI) was shared during the interaction, maintaining transparency and market fairness.
The bank has also posted the information regarding this meeting on its official website www.rbl.bank.in to comply with Regulation 46(2) of the SEBI Listing Regulations.
Highlights
- Investor meeting held on November 3, 2026, in Mumbai with ASK Asset Management Private Limited.
- Meeting type was one-on-one and conducted physically.
- No unpublished price sensitive information was shared during the meeting.
- Information regarding the meeting is accessible on RBL Bank’s official website as per SEBI regulations.
Key Data Snapshot
What happened
- RBL Bank held a one-on-one investor meeting with ASK Asset Management Private Limited on November 3, 2026.
- The meeting was conducted physically in Mumbai.
- The bank confirmed that no unpublished price sensitive information was shared during the meeting.
Regulatory and governance context
- The meeting was held pursuant to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Information about the meeting is published on RBL Bank’s website in compliance with Regulation 46(2).
- The disclosure ensures transparency to public investors and maintains market integrity.
Highlights
- Investor meeting held on November 3, 2026, in Mumbai with ASK Asset Management Private Limited.
- Meeting type was one-on-one and conducted physically.
- No unpublished price sensitive information was shared during the meeting.
- Information regarding the meeting is accessible on RBL Bank’s official website as per SEBI regulations.
Disclosures
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Regulation 30(6)
- Regulation 46(2) of SEBI Listing Regulations
More News on General / Other
View allLatest corporate announcements and market updates in General / Other.
Biocon Limited Reports Q2 FY2027 Profit of Rs. 917 Million and Announces New CTO Appointment
Biocon Limited disclosed its unaudited standalone financial results for the quarter and half year ending September 30, 2026, with a quarterly profit of Rs. 917 million. The board also approved the resignation of CTO Dr. Mandar Shrikant Ghatnekar effective December 31, 2026, and the appointment of Mr. Mukesh Rathi as CTO starting January 1, 2027.
Read Full Story
Biocon Reports Q2 FY27 Total Income of Rs 4,423 Crore With Biopharma Revenue Up 5% and $400 Million Pertuzumab Deal
Biocon Limited announced consolidated total income of Rs 4,423 crore for the second quarter of fiscal year 2027, with biopharma revenues increasing by 5% year-on-year to Rs 3,583 crore. The company's EBITDA was reported at Rs 865 crore and net profit at Rs 41 crore. A significant highlight includes securing a 10-year biosimilar Pertuzumab PDP partnership in Brazil valued at about USD 400 million.
Read Full Story
Zydus Lifesciences Posts Rs. 79,096 Million Revenue in Q2 FY27 with Net Profit at Rs. 9,255 Million
Zydus Lifesciences Limited reported strong revenue growth of 29% year-on-year in Q2 FY27 at Rs. 79,096 million, driven by its branded pharma businesses in India, North America, and international markets. However, net profit declined 27% to Rs. 9,255 million, and EBITDA dropped 6% to Rs. 18,945 million, reflecting cost and margin pressures.
Read Full Story
